Logo image
Methylene blue does not neutralize heparin after cardiopulmonary bypass
Journal article   Peer reviewed

Methylene blue does not neutralize heparin after cardiopulmonary bypass

Samuel Metz, Jan C. Horrow, Inder P. Goel, M.L.R. Kuretu, Collette Bellwoar and Jay C Horrow
Journal of cardiothoracic and vascular anesthesia, v 10(4), pp 474-476
1996
PMID: 8776640

Abstract

cardiopulmonary bypass heparin methylene blue protamine
It was hypothesized that methylene blue could neutralize heparin in patients after cardiopulmonary bypass and become an alternative to protamine. This was a prospective unblinded study with patients serving as their own controls. A single, large university hospital. This study was conducted in patients scheduled for elective aortocoronary bypass grafting. When heparin was to be neutralized, patients received methylene blue, 2 to 12 mg/kg, diluted in 50 mL and infused over 20 minutes. If a clot was not observed or the activated coagulation time (ACT) remained elevated, protamine, 250 mg, was administered and the ACT was repeated. No patient demonstrated clot after methylene blue infusion. ACT did not return to preheparin values in any patient. All patients required protamine to establish hemostasis. Protamine restored the ACT to preheparin values in every patient. The one patient who received 12 mg/kg experienced severe pulmonary hypertension. Methylene blue does not neutralize heparin after cardiopulmonary bypass.

Metrics

17 Record Views
5 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Anesthesiology
Cardiac & Cardiovascular Systems
Peripheral Vascular Disease
Respiratory System
Logo image